Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses the FDA approval of pembrolizumab (Keytruda) in the frontline setting for patients with non—small cell lung cancer (NSCLC).

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Immuno-Oncology

Immunotherapy in Lung Cancer

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses the FDA approval of pembrolizumab (Keytruda) in the frontline setting for patients with non–small cell lung cancer (NSCLC).

Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC